Biota completes new flu trial
Thursday, 31 July, 2008
Biota Holdings [ASX: BTA] has completed the Phase II trials of its influenza treatment CS-8958, with Phase III trials set to commence later this year.
CS-8958 is a long-acting neuraminidase inhibitor [LANI], and is co-owned by Daiichi-Sankyo.
Several hundred flu patients participated in the double-blind trial, which was conducted to the standards of the Japanese Pharmaceuticals and Medical Devices Agency.
The trial revealed that one dose of CS-8958 produced results indistinguishable from 75mg of oseltamivir administered twice daily for five days.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
